glycine has been researched along with Hematologic Malignancies in 10 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ivosidenib 500-mg QD has favorable pharmacokinetic and pharmacodynamic profiles in patients with advanced hematologic malignancies with an IDH1 mutation." | 9.34 | Clinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutation. ( Agresta, SV; Attar, EC; Dai, D; de Botton, S; DiNardo, CD; Fan, B; Lemieux, I; Liu, G; Liu, H; Stein, E; Yang, H, 2020) |
| "Ixazomib is an investigational proteasome inhibitor with demonstrated antitumor activity in xenograft models of multiple myeloma (MM), lymphoma, and solid tumors." | 6.80 | Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies. ( Berg, D; Berger, AJ; Di Bacco, A; Gao, F; Gupta, N; Hui, AM; Infante, JR; Kalebic, T; Kauh, JS; Lin, J; Liu, G; Siu, LL; Smith, DC; Sullivan, D; Thompson, JA; Tirrell, S; Vlahovic, G, 2015) |
| "Ivosidenib 500-mg QD has favorable pharmacokinetic and pharmacodynamic profiles in patients with advanced hematologic malignancies with an IDH1 mutation." | 5.34 | Clinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutation. ( Agresta, SV; Attar, EC; Dai, D; de Botton, S; DiNardo, CD; Fan, B; Lemieux, I; Liu, G; Liu, H; Stein, E; Yang, H, 2020) |
| "Since 2003, the US Food and Drug Administration approval of bortezomib, a proteasome inhibitor, has changed the management of hematologic malignancies and dramatically improved outcomes for patients with multiple myeloma and mantle cell lymphoma." | 4.95 | Proteasome inhibitors: structure and function. ( Annunziata, CM; Nunes, AT, 2017) |
| "Ixazomib is an investigational proteasome inhibitor with demonstrated antitumor activity in xenograft models of multiple myeloma (MM), lymphoma, and solid tumors." | 2.80 | Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies. ( Berg, D; Berger, AJ; Di Bacco, A; Gao, F; Gupta, N; Hui, AM; Infante, JR; Kalebic, T; Kauh, JS; Lin, J; Liu, G; Siu, LL; Smith, DC; Sullivan, D; Thompson, JA; Tirrell, S; Vlahovic, G, 2015) |
| "Alternate-day oral dosing of PF-04929113 at 74 mg/m(2) for 21/28 days was generally well tolerated with reversible toxicity." | 2.78 | Phase I trial of the HSP90 inhibitor PF-04929113 (SNX5422) in adult patients with recurrent, refractory hematologic malignancies. ( Brega, N; Hinson, JM; Houk, BE; Jillela, A; Reddy, N; Voorhees, PM, 2013) |
| "Volasertib is a Plk inhibitor under evaluation combined with low-dose cytarabine in older patients with acute myeloid leukemia (AML) ineligible for intensive induction therapy." | 2.53 | Polo-like kinase inhibitors in hematologic malignancies. ( Griffiths, EA; Talati, C; Wang, ES; Wetzler, M, 2016) |
| "The anticancer activity of produced carbon nanomaterial revealed that it inhibited the BTK protein and its downstream pathways, including PLC and Akt proteins, at the cellular level." | 1.91 | Identification and Biological Evaluation of a Water-Soluble Fullerene Nanomaterial as BTK Kinase Inhibitor. ( Balin, K; Calvaresi, M; Korzuch, J; Malarz, K; Marforio, TD; Mrozek-Wilczkiewicz, A; Musiol, R; Serda, M, 2023) |
| "Furthermore, hematologic malignancies arising in NrasG12D/G12D,C181S compound heterozygous mice invariably acquired revertant mutations that restored cysteine 181." | 1.56 | Genetic disruption of N-RasG12D palmitoylation perturbs hematopoiesis and prevents myeloid transformation in mice. ( Cravatt, BF; Firestone, AJ; Haigis, KM; Huang, BJ; Inguva, A; Kogan, SC; Long, AM; Predovic, M; Remsberg, JR; Shannon, K; Suciu, RM; Wong, JC; Zambetti, NA, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 3 (30.00) | 2.80 |
| Authors | Studies |
|---|---|
| Malarz, K | 1 |
| Korzuch, J | 1 |
| Marforio, TD | 1 |
| Balin, K | 1 |
| Calvaresi, M | 1 |
| Mrozek-Wilczkiewicz, A | 1 |
| Musiol, R | 1 |
| Serda, M | 1 |
| Xi, J | 1 |
| Zhuang, R | 1 |
| Kong, L | 1 |
| He, R | 1 |
| Zhu, H | 1 |
| Zhang, J | 1 |
| Zambetti, NA | 1 |
| Firestone, AJ | 1 |
| Remsberg, JR | 1 |
| Huang, BJ | 1 |
| Wong, JC | 1 |
| Long, AM | 1 |
| Predovic, M | 1 |
| Suciu, RM | 1 |
| Inguva, A | 1 |
| Kogan, SC | 1 |
| Haigis, KM | 1 |
| Cravatt, BF | 1 |
| Shannon, K | 1 |
| Fan, B | 1 |
| Dai, D | 1 |
| DiNardo, CD | 1 |
| Stein, E | 1 |
| de Botton, S | 1 |
| Attar, EC | 1 |
| Liu, H | 1 |
| Liu, G | 2 |
| Lemieux, I | 1 |
| Agresta, SV | 1 |
| Yang, H | 1 |
| Prabhu, VV | 1 |
| Talekar, MK | 1 |
| Lulla, AR | 1 |
| Kline, CLB | 1 |
| Zhou, L | 1 |
| Hall, J | 1 |
| Van den Heuvel, APJ | 1 |
| Dicker, DT | 1 |
| Babar, J | 1 |
| Grupp, SA | 1 |
| Garnett, MJ | 1 |
| McDermott, U | 1 |
| Benes, CH | 1 |
| Pu, JJ | 1 |
| Claxton, DF | 1 |
| Khan, N | 1 |
| Oster, W | 1 |
| Allen, JE | 1 |
| El-Deiry, WS | 1 |
| Nunes, AT | 1 |
| Annunziata, CM | 1 |
| Reddy, N | 1 |
| Voorhees, PM | 1 |
| Houk, BE | 1 |
| Brega, N | 1 |
| Hinson, JM | 1 |
| Jillela, A | 1 |
| Mitsiades, CS | 1 |
| Smith, DC | 1 |
| Kalebic, T | 1 |
| Infante, JR | 1 |
| Siu, LL | 1 |
| Sullivan, D | 1 |
| Vlahovic, G | 1 |
| Kauh, JS | 1 |
| Gao, F | 1 |
| Berger, AJ | 1 |
| Tirrell, S | 1 |
| Gupta, N | 1 |
| Di Bacco, A | 1 |
| Berg, D | 1 |
| Lin, J | 1 |
| Hui, AM | 1 |
| Thompson, JA | 1 |
| Talati, C | 1 |
| Griffiths, EA | 1 |
| Wetzler, M | 1 |
| Wang, ES | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation[NCT02074839] | Phase 1 | 291 participants (Anticipated) | Interventional | 2014-03-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for glycine and Hematologic Malignancies
| Article | Year |
|---|---|
Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases.
Topics: Animals; Antineoplastic Agents; Autoimmune Diseases; Boron Compounds; Bortezomib; Glycine; Hematolog | 2019 |
Proteasome inhibitors: structure and function.
Topics: Antineoplastic Agents; Boron Compounds; Bortezomib; Glycine; Hematologic Neoplasms; Humans; Lymphoma | 2017 |
Polo-like kinase inhibitors in hematologic malignancies.
Topics: 4-Aminobenzoic Acid; Azepines; Benzazepines; Cell Cycle Proteins; Clinical Trials, Phase III as Topi | 2016 |
3 trials available for glycine and Hematologic Malignancies
| Article | Year |
|---|---|
Clinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutation.
Topics: Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Mo | 2020 |
Phase I trial of the HSP90 inhibitor PF-04929113 (SNX5422) in adult patients with recurrent, refractory hematologic malignancies.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Cohort Studies; Disease Progression; Dose-Response Relat | 2013 |
Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies.
Topics: Activating Transcription Factor 3; Adult; Aged; Boron Compounds; Cohort Studies; Dose-Response Relat | 2015 |
4 other studies available for glycine and Hematologic Malignancies
| Article | Year |
|---|---|
Identification and Biological Evaluation of a Water-Soluble Fullerene Nanomaterial as BTK Kinase Inhibitor.
Topics: Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Caspases; Fullerenes; Glycine; Hematolog | 2023 |
Genetic disruption of N-RasG12D palmitoylation perturbs hematopoiesis and prevents myeloid transformation in mice.
Topics: Amino Acid Substitution; Animals; Aspartic Acid; Cell Transformation, Neoplastic; Cells, Cultured; G | 2020 |
Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies.
Topics: Activating Transcription Factor 4; Animals; Antineoplastic Agents; Apoptosis; Azacitidine; Boron Com | 2018 |
Therapeutic landscape of carfilzomib and other modulators of the ubiquitin-proteasome pathway.
Topics: Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Cell Line, Tumor; Clinical Trials | 2015 |